$280.35
1.03% yesterday
NYSE, Jun 25, 10:09 pm CET
ISIN
US0311621009
Symbol
AMGN
Sector
Industry

Amgen Stock price

$280.35
+8.69 3.20% 1M
+15.86 6.00% 6M
+19.71 7.56% YTD
-38.96 12.20% 1Y
+35.50 14.50% 3Y
+45.24 19.24% 5Y
+121.59 76.59% 10Y
+219.27 358.99% 20Y
NYSE, Closing price Wed, Jun 25 2025
+2.86 1.03%
ISIN
US0311621009
Symbol
AMGN
Sector
Industry

Key metrics

Basic
Market capitalization
$149.2b
Enterprise Value
$197.8b
Net debt
$48.6b
Cash
$8.8b
Shares outstanding
537.7m
Valuation (TTM | estimate)
P/E
25.32 | 20.66
P/S
4.37 | 4.23
EV/Sales
5.80 | 5.61
EV/FCF
18.12
P/B
24.04
Dividends
DPS
$9.00
Yield 1Y | 5Y
3.24% | 3.07%
Growth 1Y | 5Y
5.63% | 9.18%
Payout 1Y | 3Y
119.05% | 78.61%
Increased
14 Years
Financials (TTM | estimate)
Revenue
$34.1b | $35.3b
EBITDA
$14.2b | $17.2b
EBIT
$8.6b
Net Income
$5.9b | $7.2b
Free Cash Flow
$10.9b
Growth (TTM | estimate)
Revenue
15.56% | 5.55%
EBITDA
22.05% | 12.59%
EBIT
22.01%
Net Income
57.67% | 76.56%
Free Cash Flow
53.78%
Margin (TTM | estimate)
Gross
64.07%
EBITDA
41.58% | 48.67%
EBIT
25.22%
Net
17.39% | 20.47%
Free Cash Flow
31.98%
Financial Health
Equity Ratio
6.40%
Return on Equity
69.59%
ROCE
12.97%
ROIC
-
Debt/Equity
9.24
More
EPS
$10.96
FCF per Share
$20.30
Short interest
2.41%
Employees
28.00k
Rev per Employee
$1.19m
Show more

Create a Free Account to create an Amgen alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Amgen Stock Analysis

Unlock Scores for Free

Analyst Opinions

33 Analysts have issued a Amgen forecast:

16x Buy
48%
15x Hold
45%
2x Sell
6%

Analyst Opinions

33 Analysts have issued a Amgen forecast:

Buy
48%
Hold
45%
Sell
6%

Financial data from Amgen

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
34,126 34,126
16% 16%
100%
- Direct Costs 12,263 12,263
23% 23%
36%
21,863 21,863
12% 12%
64%
- Selling and Administrative Expenses 6,975 6,975
4% 4%
20%
- Research and Development Expense 6,107 6,107
21% 21%
18%
14,188 14,188
22% 22%
42%
- Depreciation and Amortization 5,580 5,580
22% 22%
16%
EBIT (Operating Income) EBIT 8,608 8,608
22% 22%
25%
Net Profit 5,933 5,933
58% 58%
17%

In millions USD.

Don't miss a Thing! We will send you all news about Amgen directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amgen Stock News

Negative
Forbes
one day ago
Amgen stock (NASDAQ:AMGN) fell 6% on Monday, June 23, 2025, after mid-stage clinical trial results for its long-acting experimental obesity drug, MariTide, revealed a need for a low starting dose to mitigate side effects like vomiting. Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase with an eight-week dose escalation period.
Neutral
Seeking Alpha
2 days ago
Amgen Inc. (NASDAQ:AMGN ) Special Call (IR Call) Conference June 23, 2025 5:30 PM ET Company Participants Justin Claeys - Vice President of Investor Relations James Bradner - Executive Vice President of Research & Development Susan Sweeney - Executive Vice President of Obesity & Related Conditions Murdo Gordon - Executive Vice President of Global Commercial Operations Conference Call Participan...
Negative
Barrons
2 days ago
At the highest dosage of MariTide, 27% of patients stopped the drug due to a gastrointestinal adverse event.
More Amgen News

Company Profile

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Head office United States
CEO Robert Bradway
Employees 28,000
Founded 1980
Website www.amgen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today